Opna Bio Reports Interim Data from Phase 1 Study on OPN-2853
Opna Bio, a forward-thinking biopharmaceutical company specializing in oncology therapeutics, has recently shared promising interim data from its lead clinical program featuring OPN-2853. This investigation is particularly focused on patients afflicted with advanced myelofibrosis. The recent findings reveal encouraging results regarding spleen reduction, coupled with a low incidence of toxicities and adverse events.
Understanding Myelofibrosis and the Impact of OPN-2853
Myelofibrosis is a serious type of blood cancer characterized by severe fibrosis in the bone marrow, leading to a host of symptoms like anemia and splenomegaly (enlarged spleen). OPN-2853 acts as a bromodomain and extra-terminal motif (BET) inhibitor, showing promise in enhancing the treatment outcomes for patients who have shown inadequate response to conventional therapies, such as ruxolitinib.
The study evaluates OPN-2853 at three different dosing levels – 20 mg, 40 mg, and 80 mg, administered orally once daily, in combination with ruxolitinib. This innovative phase 1 investigator-led study has enrolled multiple participants across various sites in a clinical setting.
According to data collected up till the cutoff date, out of the 12 evaluable patients, a significant median spleen size reduction was observed, with half of these patients showing no palpable spleen during evaluations. The combination treatment has been well tolerated by the majority of participants, many of whom have successfully completed eight cycles of treatment.
Expert Insights on the OPN-2853 Trial
Principal investigator Adam Mead, a renowned professor of hematology, expressed optimism concerning the initial findings. He noted, "The data gathered so far give us hope as they demonstrate the ability of OPN-2853, when combined with ruxolitinib, to achieve considerable therapeutic effects, especially in patients with very limited treatment options at this stage of their disease." He also indicated expectations for establishing a recommended Phase 2 dose by early 2025.
OPN-6602: A New Hope for Patients with Multiple Myeloma
In addition to OPN-2853, Opna Bio is also advancing OPN-6602, a small molecule inhibitor designed to target the E1A binding protein (EP300) and CREB-binding protein (CBP). This drug is under evaluation in a phase 1 trial for patients suffering from multiple myeloma, a neoplastic condition arising from malignant plasma cells in the bone marrow.
The preclinical findings from OPN-6602 trials showcase promising results as well, with a remarkable 71% tumor suppression noted in mouse xenograft models when used as a single agent. Remarkably, when combined with drugs like dexamethasone, pomalidomide, or mezigdomide, complete tumor regression was achieved, reflecting a significant breakthrough in treatment methodologies.
Potential Mechanisms of Action
RNA sequencing from the treated models revealed that OPN-6602 effectively downregulates pivotal multiple myeloma driver genes, presenting a potential solution to overcoming resistance issues associated with current standard treatments.
Gideon Bollag, the Chief Scientific Officer at Opna Bio, shared his enthusiasm: "Our findings highlight the unique pharmacokinetic properties of OPN-2853 and OPN-6602, affirming our approach of prioritizing safety without compromising efficacy. The drugs’ characteristics enable consistent daily dosing, leading to effective engagement with targets while minimizing adverse effects that are typically encountered with longer-acting drugs."
About Opna Bio
Opna Bio is committed to pioneering innovative cancer therapeutics, advancing multiple drug candidates aimed at various cancer mechanisms. Their extensive pipeline features OPN-2853, evaluated in myelofibrosis management alongside ruxolitinib, and OPN-6602, which is undergoing trials as an innovative treatment for multiple myeloma. The team’s proven excellence in scientific discovery and drug development is reflected in its successful navigation from concept to market-ready therapeutics.
Frequently Asked Questions
What is OPN-2853 used for?
OPN-2853 is a BET inhibitor being researched as a treatment for patients with advanced myelofibrosis.
What results have been observed in the OPN-2853 trial?
The trial has shown median spleen size reduction in evaluable patients, with half experiencing no palpable spleen post-treatment.
What role does OPN-6602 play in cancer treatment?
OPN-6602 is an EP300/CBP inhibitor currently being tested as a potential therapy for multiple myeloma.
How does Opna Bio ensure patient safety during trials?
Opna Bio emphasizes a 'safety by design' approach, focusing on pharmacokinetic properties to reduce toxicities during drug treatment.
When can we expect further results from Opna Bio's studies?
Opna Bio anticipates having a recommended Phase 2 dose for OPN-2853 by early 2025, along with ongoing evaluations for OPN-6602.
